Oxford Immunotec Global (NASDAQ:OXFD) has appointed Karen Koski as head of strategy and investor relations, a newly created position that will report directly to CEO, Peter Wrighton-Smith. The appointment is effective on June 21.
Dr. Wrighton-Smith said Ms. Koski is not only extremely knowledgeable about the diagnostics and blood banking industries, but also is very familiar with Oxford’s story and long-term strategy.
“Karen’s professional experience and knowledge of our industry will be invaluable as we execute on our strategic growth plans and work to maximize shareholder value.”
Ms. Koski most recently was a director and senior equity analyst at BTIG, where she covered companies in the medical technology, life sciences, and diagnostics sectors. Prior to BTIG, she worked as an equity research associate at Lazard Capital Markets.
